Company Filing History:
Years Active: 2004-2007
Title: The Innovative Contributions of Lawrence W. Anderson
Introduction
Lawrence W. Anderson is an accomplished inventor based in Wheaton, MD, whose contributions to the field of oncology have resulted in eight patents. His pioneering work in the imaging of drug accumulation plays a vital role in improving antitumor therapies, benefiting countless patients.
Latest Patents
Anderson's latest patents focus on the use of radio-labeled antitumor drugs for the treatment of solid tumors. One of his notable inventions describes methods for administering a radio-labeled anticancer drug to a patient and imaging the patient using Positron Emission Tomography (PET). This innovative technique allows healthcare professionals to monitor drug delivery to tumors and predict the effectiveness of various therapeutic options. Particularly preferred drugs mentioned in his patents include labeled taxanes such as C-paclitaxel and C-docetaxel, as well as labeled anthracyclines like C-doxorubicin and C-epirubicin. These advancements are pivotal for individualizing therapy and evaluating the effectiveness of anti-cancer drugs for specific cancers.
Career Highlights
Throughout his career, Lawrence W. Anderson has made significant strides in the field of medical innovations. His work is predominantly conducted under the aegis of the United States of America, as represented by the Secretary of the Department of Health and Human Services. The impact of his inventions has far-reaching implications for cancer treatment and research.
Collaborations
Anderson has collaborated with esteemed colleagues Raymond W. Klecker, Jr. and Jerry M. Collins, contributing to a dynamic team focused on advancing cancer therapies. Their collective expertise enhances the innovations Anderson has developed, fostering a collaborative environment that encourages the exchange of ideas and insights.
Conclusion
Lawrence W. Anderson exemplifies the spirit of innovation in the field of medicine, particularly through his work on radio-labeled antitumor drugs. With his extensive patent portfolio and collaborative efforts, he continues to push the boundaries of cancer treatment, offering hope and improved outcomes for patients battling solid tumors.